1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow LIN YANG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer trifluridine/tipiracil (TAS-102), bevacizumab plus camrelizumab - Gastric Cancer Adenocarcinoma Metastatic | Phase 2 | Recruiting | LIN YANG | 31 | 2024-11-14 | 2024-12-02 |
Bevacizumab (1) · Trifluridine (1) · camrelizumab (1) · tipiracil (1) · trifluridine tipiracil drug combination (1)
China (1)